IQVIA Holdings Inc. (NYSE:IQV) Given Consensus Recommendation of “Buy” by Analysts

IQVIA Holdings Inc. (NYSE:IQV) has been given an average rating of “Buy” by the seventeen ratings firms that are presently covering the firm, MarketBeat.com reports. Two research analysts have rated the stock with a hold recommendation, thirteen have given a buy recommendation and two have given a strong buy recommendation to the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $229.1250.

A number of equities analysts have recently issued reports on the company. Royal Bank Of Canada started coverage on IQVIA in a research note on Tuesday, March 3rd. They set an “outperform” rating and a $221.00 target price for the company. Barclays upgraded IQVIA from an “equal weight” rating to an “overweight” rating and set a $210.00 price objective for the company in a research report on Friday, March 6th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of IQVIA in a research note on Thursday, January 22nd. Morgan Stanley set a $240.00 price target on shares of IQVIA in a report on Wednesday, February 11th. Finally, Evercore reissued an “outperform” rating and set a $225.00 price objective on shares of IQVIA in a report on Thursday, February 5th.

IQVIA Stock Up 2.1%

Shares of IQVIA stock opened at $169.05 on Friday. IQVIA has a one year low of $134.65 and a one year high of $247.04. The company has a market cap of $28.69 billion, a P/E ratio of 21.51, a PEG ratio of 1.60 and a beta of 1.39. The company has a debt-to-equity ratio of 2.09, a quick ratio of 0.75 and a current ratio of 0.75. The firm has a fifty day moving average of $188.18 and a two-hundred day moving average of $205.38.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Thursday, February 5th. The medical research company reported $3.42 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.40 by $0.02. The business had revenue of $4.36 billion for the quarter, compared to analyst estimates of $4.24 billion. IQVIA had a net margin of 8.34% and a return on equity of 30.50%. The business’s revenue was up 10.3% compared to the same quarter last year. During the same period in the previous year, the business posted $3.12 earnings per share. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. On average, analysts forecast that IQVIA will post 10.84 earnings per share for the current year.

Institutional Investors Weigh In On IQVIA

A number of institutional investors and hedge funds have recently modified their holdings of IQV. Vanguard Group Inc. increased its stake in IQVIA by 0.8% in the 4th quarter. Vanguard Group Inc. now owns 19,650,532 shares of the medical research company’s stock valued at $4,429,426,000 after purchasing an additional 159,899 shares in the last quarter. Geode Capital Management LLC grew its holdings in IQVIA by 0.6% in the fourth quarter. Geode Capital Management LLC now owns 4,374,971 shares of the medical research company’s stock valued at $982,272,000 after purchasing an additional 24,453 shares during the last quarter. Boston Partners increased its position in shares of IQVIA by 14.9% in the fourth quarter. Boston Partners now owns 4,087,380 shares of the medical research company’s stock valued at $923,276,000 after buying an additional 530,672 shares in the last quarter. JPMorgan Chase & Co. raised its stake in shares of IQVIA by 16.2% during the 4th quarter. JPMorgan Chase & Co. now owns 3,799,600 shares of the medical research company’s stock worth $856,468,000 after buying an additional 528,753 shares during the last quarter. Finally, Alliancebernstein L.P. boosted its position in shares of IQVIA by 1.2% in the 3rd quarter. Alliancebernstein L.P. now owns 3,597,572 shares of the medical research company’s stock worth $683,323,000 after buying an additional 41,643 shares in the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.